Literature DB >> 19515410

Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

Adam G Tabák1, Markus Jokela, Tasnime N Akbaraly, Eric J Brunner, Mika Kivimäki, Daniel R Witte.   

Abstract

BACKGROUND: Little is known about the timing of changes in glucose metabolism before occurrence of type 2 diabetes. We aimed to characterise trajectories of fasting and postload glucose, insulin sensitivity, and insulin secretion in individuals who develop type 2 diabetes.
METHODS: We analysed data from our prospective occupational cohort study (Whitehall II study) of 6538 (71% male and 91% white) British civil servants without diabetes mellitus at baseline. During a median follow-up period of 9.7 years, 505 diabetes cases were diagnosed (49.1% on the basis of oral glucose tolerance test). We assessed retrospective trajectories of fasting and 2-h postload glucose, homoeostasis model assessment (HOMA) insulin sensitivity, and HOMA beta-cell function from up to 13 years before diabetes diagnosis (diabetic group) or at the end of follow-up (non-diabetics).
FINDINGS: Multilevel models adjusted for age, sex, and ethnic origin confirmed that all metabolic measures followed linear trends in the group of non-diabetics (10,989 measurements), except for insulin secretion that did not change during follow-up. In the diabetic group (801 measurements), a linear increase in fasting glucose was followed by a steep quadratic increase (from 5.79 mmol/L to 7.40 mmol/L) starting 3 years before diagnosis of diabetes. 2-h postload glucose showed a rapid increase starting 3 years before diagnosis (from 7.60 mmol/L to 11.90 mmol/L), and HOMA insulin sensitivity decreased steeply during the 5 years before diagnosis (to 86.7%). HOMA beta-cell function increased between years 4 and 3 before diagnosis (from 85.0% to 92.6%) and then decreased until diagnosis (to 62.4%).
INTERPRETATION: In this study, we show changes in glucose concentrations, insulin sensitivity, and insulin secretion as much as 3-6 years before diagnosis of diabetes. The description of biomarker trajectories leading to diabetes diagnosis could contribute to more-accurate risk prediction models that use repeated measures available for patients through regular check-ups. FUNDING: Medical Research Council (UK); Economic and Social Research Council (UK); British Heart Foundation (UK); Health and Safety Executive (UK); Department of Health (UK); National Institute of Health (USA); Agency for Health Care Policy Research (USA); the John D and Catherine T MacArthur Foundation (USA); and Academy of Finland (Finland).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515410      PMCID: PMC2726723          DOI: 10.1016/S0140-6736(09)60619-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  42 in total

1.  The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes.

Authors:  M M Gabir; R L Hanson; D Dabelea; G Imperatore; J Roumain; P H Bennett; W C Knowler
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

2.  Tutorial in Biostatistics: Evaluating the impact of 'critical periods' in longitudinal studies of growth using piecewise mixed effects models.

Authors:  E N Naumova; A Must; N M Laird
Journal:  Int J Epidemiol       Date:  2001-12       Impact factor: 7.196

3.  Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?

Authors:  Michael P Stern; Ken Williams; Steven M Haffner
Journal:  Ann Intern Med       Date:  2002-04-16       Impact factor: 25.391

4.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Authors:  J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

5.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

6.  Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

Authors: 
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

7.  Long-term changes and variability in diabetes risk factors prior to the development of impaired glucose homeostasis.

Authors:  E Laspa; A Christen; Z Efstathiadou; D G Johnston; I F Godsland
Journal:  Diabet Med       Date:  2007-09-26       Impact factor: 4.359

8.  The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging.

Authors:  James B Meigs; Denis C Muller; David M Nathan; Deirdre R Blake; Reubin Andres
Journal:  Diabetes       Date:  2003-06       Impact factor: 9.461

9.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

10.  Mode of onset of type 2 diabetes from normal or impaired glucose tolerance.

Authors:  Ele Ferrannini; Monica Nannipieri; Ken Williams; Clicerio Gonzales; Steve M Haffner; Michael P Stern
Journal:  Diabetes       Date:  2004-01       Impact factor: 9.461

View more
  302 in total

1.  Soluble and cell-associated insulin receptor dysfunction correlates with severity of HAND in HIV-infected women.

Authors:  Yamil Gerena; Richard L Skolasky; Joyce M Velez; Dianedis Toro-Nieves; Raul Mayo; Avindra Nath; Valerie Wojna
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

2.  Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.

Authors:  Hiroyuki Inoue; Yoko Tamaki; Yushi Kashihara; Shota Muraki; Makoto Kakara; Takeshi Hirota; Ichiro Ieiri
Journal:  Br J Clin Pharmacol       Date:  2018-12-06       Impact factor: 4.335

3.  The effect of steroid pulse therapy on carbohydrate metabolism in multiple myeloma patients: a randomized crossover observational clinical study.

Authors:  O Véber; A Wilde; J Demeter; G Tamás; I Mucsi; A G Tabák
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

4.  Strategies for preventing type 2 diabetes: an update for clinicians.

Authors:  Kaivan Khavandi; Halima Amer; Bashar Ibrahim; Jack Brownrigg
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

Review 5.  Diabetes prevention: can insulin secretagogues do the job?

Authors:  Barbara Westerhaus; Aidar R Gosmanov; Guillermo E Umpierrez
Journal:  Prim Care Diabetes       Date:  2010-12-24       Impact factor: 2.459

6.  Not performing an OGTT results in significant underdiagnosis of (pre)diabetes in a high risk adult Caucasian population.

Authors:  A S Meijnikman; C E M De Block; E Dirinck; A Verrijken; I Mertens; B Corthouts; L F Van Gaal
Journal:  Int J Obes (Lond)       Date:  2017-07-19       Impact factor: 5.095

7.  Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP).

Authors:  Tamara S Hannon; M S Kirkman; Yash R Patel; Robert V Considine; Kieren J Mather
Journal:  Diabetes Metab Res Rev       Date:  2014-11       Impact factor: 4.876

8.  The Ups and Downs of Insulin Resistance and Type 2 Diabetes: Lessons from Genomic Analyses in Humans.

Authors:  Vicencia Sales; Mary-Elizabeth Patti
Journal:  Curr Cardiovasc Risk Rep       Date:  2012-12-09

Review 9.  Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk.

Authors:  Chee W Chia; Josephine M Egan; Luigi Ferrucci
Journal:  Circ Res       Date:  2018-09-14       Impact factor: 17.367

10.  Insulin therapy and the risk of colorectal cancer in patients with type 2 diabetes: a meta-analysis of observational studies.

Authors:  Wu-jie Bu; Lei Song; Dan-yi Zhao; Bing Guo; Jing Liu
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.